Your browser doesn't support javascript.
loading
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Plummer, Ruth; Lorigan, Paul; Steven, Neil; Scott, Lucy; Middleton, Mark R; Wilson, Richard H; Mulligan, Evan; Curtin, Nicola; Wang, Diane; Dewji, Raz; Abbattista, Antonello; Gallo, Jorge; Calvert, Hilary.
Affiliation
  • Plummer R; Institute for Cancer Research, Paul O'Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK. ruth.plummer@ncl.ac.uk
Cancer Chemother Pharmacol ; 71(5): 1191-9, 2013 May.
Article in En | MEDLINE | ID: mdl-23423489
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Poly(ADP-ribose) Polymerase Inhibitors / Melanoma Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2013 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Skin Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Poly(ADP-ribose) Polymerase Inhibitors / Melanoma Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 2013 Document type: Article Affiliation country: